Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00439361|
Recruitment Status : Completed
First Posted : February 23, 2007
Last Update Posted : July 9, 2012
- To determine the toxicity profile of multiple doses of bortezomib when given with ICE in patients with relapsed and refractory classical Hodgkin lymphoma (HL).
- To determine the maximum tolerated dose (MTD) of bortezomib when given in combination with ICE chemotherapy in patients with relapsed and refractory classical Hodgkin lymphoma (HL).
- To determine the overall response rate and complete response rate in patients with relapsed and refractory classical Hodgkin lymphoma (HL).
|Condition or disease||Intervention/treatment||Phase|
|Hodgkin Lymphoma Lymphoma||Drug: Bortezomib Drug: Carboplatin Drug: Etoposide Drug: Ifosfamide Drug: Mesna||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase-I Study of Bortezomib (VELCADE) Plus ICE (Ifosfamide, Carboplatin, Etoposide) for Patients With Relapsed Classical Hodgkin Lymphoma|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
U.S. FDA Resources
Experimental: Bortezomib + ICE
Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):
Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours.
1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
Other Names:Drug: Carboplatin
5 AUC by Vein Over 1 Hour On Day 1
Other Name: Paraplatin®Drug: Etoposide
100 mg/m^2 By Vein Over 2 Hours On Days 1-3
Other Name: VePesid®Drug: Ifosfamide
5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1Drug: Mesna
5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
Other Name: Mesnex
- Maximum Tolerable Dose (MTD) of Bortezomib when given in combination with ICE chemotherapy in participants with relapsed and refractory classical Hodgkin lymphoma (HL) [ Time Frame: Two-week cycle ]MTD dose escalation stops either at the highest indicated dose of bortezomib (1.5 mg/m2), or when a Dose limiting toxicity (DLT) has been observed in at least one third of the patients at any dose level.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00439361
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Michelle A. Fanale, MD||M.D. Anderson Cancer Center|